MULTIPLE SCLEROSIS THERAPEUTICS

by Rudick; Richard

• ISBN13: 9781853178122
• ISBN10: 1853178128
• Edition: 1st
• Format: Hardcover
• Copyright: 1999-09-01
• Publisher: CRC Press

Summary

This revised textbook examines the most important aspects of multiple sclerosis that impact on clinical trial design, on the development of new disease therapies, and, very importantly, on patient care. The international team of contrib4tors discusses the clinical course of multiple sclerosis, its clinical heterogeneity, and the presence of subclinical disease activity that occurs during the early stages of the disease. There have been substantial advances in the field since the first edition was published in 1999. The previous chapters have been updated to reflect these new findings, and several new chapters have been added. Multiple sclerosis presents substantial clinical challenges, from unexpected and irregular relapses to progressive deterioration. The reader will find help with these challenges in Multiple Sclerosis Therapeutics (Second edition).

Table of Contents

Contributors	p. xi
Preface to first edition	p. xix
Preface to second edition	p. xxi
Acknowledgements	p. xxiii
Introduction
Aspects of multiple sclerosis that relate to clinical trial design and treatment	p. 3
Clinical trial methodology
Measures of neurologic impairment and disability in multiple sclerosis	p. 23
Assessment of neuropsychological function in multiple sclerosis	p. 37
Health-related quality of life assessment in multiple sclerosis	p. 61
Magnetic resonance imaging in multiple sclerosis: an overview	p. 81
Measures of gadolinium enhancement in multiple sclerosis	p. 97
Measures of magnetization transfer in multiple sclerosis	p. 125
Measures of T1 and T2 relaxation in multiple sclerosis	p. 155
Measurement of central nervous system atrophy in multiple sclerosis	p. 173
Measures to quantify axonal damage in vivo based on magnetic resonance spectroscopy in multiple sclerosis	p. 193
Functional imaging in multiple sclerosis	p. 207
Use of cost analyses to improve our understanding of the therapeutic trade-offs for multiple sclerosis	p. 221
Ethical considerations in multiple sclerosis clinical trials	p. 231
The process of drug development and approval in the USA, the European Union and Canada	p. 241
Sponsors, monitoring committees and investigators: the investigator's perspective	p. 257
Guidelines for clinical trials of new therapeutic agents in multiple sclerosis: reporting extended results from phase III clinical trials	p. 261
The failed clinical trial in multiple sclerosis	p. 267
The challenge of long-term studies in multiple sclerosis: use of pooled data, historical controls, and observational studies to determine efficacy	p. 277
Emerging concepts of pathogenesis: relationship to MS therapies	p. 289
Clinical trials of disease-modifying therapy
Interferons in relapsing-remitting multiple sclerosis	p. 325
Interferons in secondary progressive multiple sclerosis	p. 347
Biological responses to type I interferons: relationship to therapeutic effects in multiple sclerosis	p. 363
Glatiramer acetate as therapy for multiple sclerosis	p. 379
Use of mitoxantrone to treat multiple sclerosis	p. 403
Intravenous immunoglobulin to treat multiple sclerosis	p. 427
Therapeutic plasma exchange for multiple sclerosis	p. 445
Treatment of multiple sclerosis with methylprednisolone	p. 461
Cyclophosphamide treatment of multiple sclerosis	p. 483
Treatment of multiple sclerosis by hematopoietic stem cell transplantation	p. 501
Emerging disease-modifying therapies for multiple sclerosis	p. 515
Combination therapies in multiple sclerosis	p. 523
Sex hormones and other pregnancy-related factors with therapeutic potential in multiple sclerosis	p. 535
Complementary and alternative treatments in multiple sclerosis	p. 551
Disease-modifying drug therapy in clinical practice
Disease-modifying drug therapy for multiple sclerosis in clinical practice	p. 567
Treatment for patients with primary progressive multiple sclerosis	p. 589
Fatigue in multiple sclerosis	p. 599
Management of spasticity in multiple sclerosis	p. 609
Management of bladder and sexual dysfunction in multiple sclerosis	p. 621
Treatment of disorders of mood and affect in multiple sclerosis	p. 651
Treatment of pain, paresthesias, and paroxysmal disorders in multiple sclerosis	p. 689
Treatment of tremor caused by multiple sclerosis	p. 705
Management of cognitive impairment in multiple sclerosis	p. 715
Rehabilitation in multiple sclerosis patients	p. 729
Table of Contents provided by Syndetics. All Rights Reserved.